A 2026 scoping review by Frederickson and colleagues mapped AI tool types and uses for acne diagnosis and management. People using acne apps can compare acne apps with four practical checks: peer-reviewed evidence, FDA authorization, CE marking, and dermatologist involvement.
A scoping review is a study that maps published research on a topic. The review screened PubMed, Cochrane and Scopus and included 105 articles, according to Wiley in the International Journal of Dermatology the review record. Most papers covered diagnosis only, with 96.2% on diagnosis, 9.5% on management only, and 5.7% on both.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 review covers
- How can you compare acne apps?
- What do accuracy numbers mean?
- Who should be most cautious?
What the 2026 review covers
The review appeared in the International Journal of Dermatology in March 2026, volume 65, pages 437-443, after online release on Nov. 6, 2025. PubMed lists Frederickson and colleagues as authors assessing AI for acne diagnosis and management the PubMed record. The main finding for shoppers is focus.
Research concentrates on diagnosis, not treatment plans or long-term care. An app may therefore analyze a photo without guiding next steps. Use this focus when reading app claims. Photo analysis is the tested use. Treatment advice has thinner research support.
How can you compare acne apps?
A JAMA Dermatology review of 41 AI dermatology apps offers four checks, as reported by MDedge the MDedge summary. Look for peer-reviewed supporting evidence, FDA authorization, CE marking, and dermatologist involvement in development.
Apply the checks before trusting a result: Few apps pass these checks. In that 41-app review, only about 12% had peer-reviewed evidence, none had FDA approval, only about 5% had CE marking, and fewer than 40% reported dermatologist input.
- Peer-reviewed study naming the app and acne result
- FDA authorization for the specific acne use
- CE marking for the specific dermatology use
- Named dermatologists involved in building or testing the app
What do accuracy numbers mean?
The strongest published app-level acne result comes from the Tibot AI cross-sectional study. It reported 91.7% top-1 prediction accuracy for acne and 96.1% mean accuracy across conditions for top-3 predictions, according to JMIR Dermatology via PMC the study record. Top-1 means the app's first answer was acne. Top-3 means acne appeared among its first three answers.
A high score in one study does not prove everyday accuracy across phones, lighting, and skin tones. Approval status is stricter than marketing language. No consumer app claiming to diagnose skin conditions including acne has FDA approval. The only FDA-cleared AI dermatology device is DermaSensor for skin-cancer triage in primary care, authorized Jan. 17, 2024.
Who should be most cautious?
People with darker skin face the largest data gap. The two largest public acne image sets, ACNE04 and AcneSCU, contain only Han Chinese subjects. A January 2026 Cureus test found ChatGPT, Rash Detector, Rash ID and Skin Scanner performed poorly on diverse skin tones. This gap can change a result.
An app trained on narrow images may miss or mislabel acne on underrepresented skin. Check whether the app shows testing across skin tones before relying on its labels. Treat acne apps as information, not diagnosis. The American Academy of Dermatology states AI should support but not replace the physician-patient relationship because unvalidated apps may give inaccurate advice. Save clear photos, list products and symptoms, and ask a dermatologist about anything persistent, painful, scarring, or worsening.
You Might Also Like
- Artificial Intelligence for Acne Diagnosis in a 2026 Scoping Review: How People Using Acne Apps Can Avoid AI Hype
- Subcision With Suction for Acne Scars in a 2026 Split-Face Trial: How People With Atrophic Acne Scars Can Compare Acne Scar Procedures
- Spironolactone, Metformin, and Bicalutamide for Acne in a 2026 Review: How Adults With Persistent Acne Can Compare Treatment Options